Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Comparison of immunochemical fecal occult blood tests for colorectal cancer screening

A study in May's issue of Gastroenterology compares immunochemical Fecal Occult Blood Tests for Colorectal Cancer Screening

News image

Quantitative fecal immunochemical tests identify individuals with colorectal cancer with greater levels of accuracy than guaiac tests.

Dr Thibaut Raginel and colleagues from  France compared the performances of 2 fecal immunochemical tests in a population undergoing screening for colorectal cancer.

The research team collected fecal samples from 19,797 individuals in France who participated in a colorectal cancer screening program, from 2009 through 2011.

Samples were analyzed using the Magstream and OC Sensor fecal immunochemical tests, as well as the Hemoccult II guaiac test.

The doctors reported that colonoscopies were performed for patients with positive results from all 3 tests.

The cut-off values for levels of hemoglobin in buffer and stools were 55 ng/mL and 180 μg/g for the Magstream and 150 ng/mL, and 30 μg/g for the OC Sensor, respectively.

The doctors found that the results from the fecal immunochemical tests were compared with those from the guaiac test for cut-off values for stool samples, positivity rates, and the receiver operating characteristic curve values.

The numbers needed to screen and the numbers needed to scope to detect an advanced neoplasia were calculated.

Numbers needed to screen were 66 for a 1-sample Magstream fecal immunochemical tests
Gastroenterology

A positive test result was found in 1224 participants.

The research team reported 1075 underwent a colonoscopy examination.

Of these, 334 were found to have advanced neoplasia.

Considering the cut-off values associated with the positivity rate of Hemoccult II, the numbers needed to screen were 239 for Hemoccult II, 166 for a 1-sample Magstream fecal immunochemical tests, and 129 for a 1-sample OC Sensor fecal immunochemical tests.

The team found that the numbers needed to scope were 3.3, 2.3, and 1.8, respectively.

For the same false-positive rate as Hemoccult II, the true-positive rates for Magstream and OC Sensor fecal immunochemical tests were 0.65% and 0.90% respectively, compared with 0.42% for Hemoccult II.

The OC Sensor fecal immunochemical tests had a greater area under the receiver operating characteristic curve value than the Magstream fecal immunochemical tests.

Dr Thibaut's team commented "Based on results from a large, population-based study, the OC Sensor fecal immunochemical tests identifies patients with colorectal cancer with greater accuracy than the Magstream fecal immunochemical tests."

Gastroenterology 2013: 144(5) :918-925
10 May 2013

Go to top of page Email this page Email this page to a colleague

 24 May 2015

Advanced search
 22 May 2015 
Colonoscopy screening for colorectal cancer
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 20 May 2015 
Refractory metastatic colorectal cancer
 19 May 2015 
Metabolic syndrome and Barrett's
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 18 May 2015 
ESPGHAN celiac guidelines
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us